LYRA · As filed with the SEC
Lyra Therapeutics cash flow statement, by fiscal year
The statement as Lyra Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | (28,919,000) | (93,435,000) | (62,680,000) | (55,278,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 2,335,000 | 6,716,000 | 5,887,000 | 5,447,000 |
| Depreciation expense | 459,000 | 471,000 | 278,000 | 1,067,000 |
| Impairment of property and equipment | — | 1,883,000 | 1,592,000 | 1,316,000 |
| Write-off of deferred financing costs | — | 140,000 | — | — |
| Impairment of right-of-use assets | — | 22,836,000 | — | — |
| Gain on sale of property and equipment | (8,000) | — | — | — |
| Net amortization of discount on short-term investments | — | (2,276,000) | (3,496,000) | (492,000) |
| Changes in operating assets and liabilities | ||||
| Prepaid expenses and other current assets | 2,069,000 | (380,000) | 867,000 | (764,000) |
| Operating lease right-of-use assets | 3,132,000 | 1,353,000 | (5,137,000) | (868,000) |
| Other assets | — | 1,111,000 | 210,000 | (574,000) |
| Accounts payable | (516,000) | (1,887,000) | 450,000 | (2,411,000) |
| Accrued expenses and other current liabilities | — | — | 1,491,000 | 4,772,000 |
| Accrued expenses and other current liabilities | (1,811,000) | (5,975,000) | — | — |
| Restructuring liability | — | 4,347,000 | — | — |
| Restructuring liability | (1,081,000) | — | — | — |
| Operating lease liabilities | (4,121,000) | (3,381,000) | (1,208,000) | 763,000 |
| Deferred revenue | (398,000) | (1,534,000) | (1,558,000) | 3,637,000 |
| Net cash used in operating activities | (28,859,000) | (70,011,000) | (63,304,000) | (43,385,000) |
| Cash flows from investing activities: | ||||
| Purchases of property and equipment | (116,000) | (2,338,000) | (1,047,000) | (164,000) |
| Proceeds from maturities of investments | — | — | 110,886,000 | — |
| Proceeds from the sale of property and equipment | 18,000 | — | — | — |
| Purchases of short-term investments | — | (47,949,000) | (122,423,000) | (64,842,000) |
| Maturity of short-term investments | — | 130,592,000 | — | — |
| Net cash (used in) provided by investing activities | (98,000) | 80,305,000 | (12,584,000) | (65,006,000) |
| Cash flows from financing activities: | ||||
| Proceeds from sale of common stock and pre-funded warrants | — | — | — | 100,495,000 |
| Proceeds from sale of common stock, warrants and pre-funded warrants | — | 8,818,000 | 69,242,000 | — |
| Proceeds from sale of common stock, warrants and pre-funded warrants | 4,999,000 | — | — | — |
| Payment of deferred offering costs | (726,000) | (290,000) | (3,654,000) | (4,246,000) |
| Proceeds from exercise of stock options | — | 3,000 | 103,000 | 8,000 |
| Net cash provided by financing activities | 4,273,000 | 8,531,000 | 65,691,000 | 96,257,000 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (24,684,000) | 18,825,000 | (10,197,000) | (12,134,000) |
| Cash, cash equivalents and restricted cash, beginning of period | 42,570,000 | 23,745,000 | 33,942,000 | 46,076,000 |
| Cash, cash equivalents and restricted cash, end of period | 17,886,000 | 42,570,000 | 23,745,000 | 33,942,000 |
| Supplemental disclosure of non-cash financing and investing activities: | ||||
| Property and equipment purchases included in accounts payable and accrued expenses | — | — | 623,000 | — |
| Other Assets Included in Accounts Payable and Accrued Expenses | — | — | — | 1,960,000 |
| Prepaid expenses for right-of-use asset included in operating lease liabilities | — | — | 2,786,000 | — |
| Modification of lease agreement | — | — | 4,931,000 | 1,928,000 |
| Right-of-use asset in exchange for lease liability | — | — | 18,156,000 | — |
| Other assets included in accounts payable and other current liabilities | — | 13,667,000 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.